Panicucci is the vice president of pharmaceutical development at STA Pharmaceutical, a WuXi AppTec company.
At WuXi, he is responsible for providing scientific leadership in the areas of developability, formulation development and good manufacturing practice.
Prior to WuXi he held the position of global head of chemical and pharmaceutical profiling at Novartis from 2004 to 2015, where he led the development and implementation of innovative dosage form designs and continuous manufacturing paradigms.
"Rick has played an important role in the early stages of drug discovery and deal making for various companies. We are very pleased to have him join our board and welcome the vast experience and oversight he brings,” said Denis Corin, the chairman and chief executive officer of Q BioMed.
"Having Rick join us as an independent director, is an important corporate governance step as we seek to up-list to a national exchange this year," Corin added.